MLTX

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) | Rumor.io

MoonLake Immunotherapeutics

MLTX

Attention (50-day avg)0.01%

Attention rank (50-day avg)#656

Bullish sentiment (50-day avg)67%

Price to earnings ratio-3.27

Market capitalization983.8M

Earnings per share-3.84

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-230.3M

Social

What share of all stock conversation is about MLTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% -0.01	0.01% +0.01

Sep 29

The company's drug is expected to submit a BLA (Biologics License Application) and is worth an estimated $400 million, which may not be a significant commercial opportunity.
The company's BLA submission is expected by the end of September, and the stock's current valuation is approximately $545 million, with a pro forma cash balance of $565 million.
The company's short fee rate is increasing, suggesting that there is a struggle to find shares to continue the shorts, and the stock has dropped to $12.04, with some investors feeling beaten up.

Generated by AI

Sentiment

Of the messages about MLTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	84.38% +28.13	65.06% +5.51	68.39% -4.47	82.73% +21.88
Bearish	15.63% -28.13	34.94% -5.51	31.61% +4.47	17.27% -21.88

Bullish· Aug 13

MoonLake Immunotherapeutics is expected to receive approval for its blockbuster drug within 4-5 months, which could significantly impact the stock price.
H.C. Wainwright has upgraded MoonLake's price target to $50, citing the drug's potential and the company's progress.
The company's recent ACR50 result of 42% could be a catalyst for further growth, as at least one analyst is not interpreting it as thesis-breaking.

Bearish· Sep 11

The company's management has been criticized for its communication, with some investors expressing frustration over the lack of updates on important trial data and conference events.
The stock has experienced significant price drops, with some investors suggesting that the company's valuation is now pricing a major failure, and that the pricing is "insane".
The company's management has been accused of playing games and making mistakes, and the recent price action has been attributed to funds dumping and retail investors being "along for the ride".

Generated by AI

Topics

Of the messages about MLTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	78.57%	95.61%	25.49%
Technical Analysis	—	21.43%	3.9%	14.75%
Analysts	—	0%	0.49%	33.55%
Controversies	—	0%	0%	1.71%
Earnings	—	0%	0%	0.93%
Macro	—	0%	0%	23.57%

Analysts· Jan 15

Goldman Sachs analyst Richard Law downgraded MoonLake Immunotherapeutics ($MLTX) to Sell from Neutral, citing high approval risks despite progress in Phase 3 trials.
The downgrade was met with skepticism by some, who pointed out that the analyst's previous upgrade and price target had been overly optimistic, and that the company's Phase 3 trials had shown promising results.
Multiple analysts, including Clear Street, H.C. Wainwright, and BTIG, have set price targets for $MLTX ranging from $24 to $45, indicating a bullish outlook for the company.

Announcements· Jun 22

MoonLake Immunotherapeutics reported strong one-year Phase 3 results for its lead HS treatment, Sonelokimab, with a 10%+ advantage over a competing IL-17 inhibitor.
The company announced positive findings from its Phase 3 VELA-1 and VELA-2 studies of sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, with 67.2% of treated patients achieving a HiSCR75 response at 52 weeks.
MoonLake Immunotherapeutics announced a proposed public offering of up to $150 million to fund commercialization, leverage positive data, strengthen negotiating power, and de-risk regulatory timelines for its sonelokimab program.

Technical Analysis· Jan 8

$MLTX is breaking out of its lower high in the mid 16s, with a potential base forming over the previous high in line with VWAP/EMA support.
The stock's structure is still biased towards the $20 area, with a trendline breakout attempt failing but a second attempt looking stronger and potentially pushing toward VWAP.
A reclaim of the VWAP and a downtrend trendline break could flip the stock into a clear uptrend toward the $20S, but short and rebuy pressure may need to be reloaded before a strong price reaction.

Generated by AI

Community

Of the messages about MLTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	89.71%	91.82%	79.91%	47.68%
Newcomers	10.29%	8.18%	20.09%	52.32%

Regulars· Sep 29

The regulars are discussing the upcoming BLA (Biologics License Application) submission, with some expressing concern that it may be delayed beyond the end of September.
The potential commercial value of the drug is being debated, with some estimating that Merck could generate $2B+ with a good commercial effort, but questioning whether the current management team has the interest or ability to build a commercial business.
The regulars are also discussing the short fee rate for $MLTX, which is finally starting to move upward, and speculating that the shorts may be struggling to find shares to continue their positions.

Newcomers· Sep 11

The recent stock drop to $11.95 and subsequent recovery to $18.49 has raised concerns about the company's management, with some users criticizing the lack of communication and transparency from the company's leadership.
The uncertainty surrounding the company's prospects, particularly with regards to the IZAR/VELA studies and the potential for a buyout or going solo, has led to a decline in the stock's value and a reevaluation of the company's worth.
The company's management is under scrutiny, with some users questioning the CEO's decisions, such as the handling of the conference fireside chat, the recent stock drop, and the lack of a webcast for shareholders, which has led to a decline in the stock's value and a loss of confidence among investors.

Generated by AI

News

Cantor Fitzgerald reiterates Moonlake stock rating at Overweight

13d agoInvesting.com

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy

21d agoSeeking Alpha

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland, August 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive...

1mo agoBarchart.com

MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital

Tipranks Press Release.

1mo agotheglobeandmail.com

MoonLake Immunotherapeutics (MLTX) Gets a Buy from BTIG

Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

Detailed price information for Moonlake Immunotherapeutics (MLTX-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about MLTX also mention

#	Name	Attention
1	SLRN - Acelyrin, Inc.	——
2	Mineralys Therapeutics, Inc.MLYS	0%+0
3	Apogee Therapeutics, Inc. - Common StockAPGE	0%0
4	Janux Therapeutics, Inc.JANX	0%0
5	Abivax SAABVX	0.01%-0.01
6	Revolution Medicines, Inc.RVMD	0.01%-0.01
7	Biomea Fusion Inc.BMEA	0.01%-0.01
8	Replimune Group, Inc.REPL	0%0
9	Mirum Pharmaceuticals, Inc.MIRM	0%0
10	Defiance Daily Target 2X Short IONQ ETFIONZ	0%0

MoonLake Immunotherapeutics Class A Ordinary Shares

Healthcare
Biotechnology

MoonLake Immunotherapeutics Class A Ordinary Shares represent ownership in MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases. The company’s lead program is Sonelokimab, a tri-specific Nanobody designed to inhibit IL-17A and IL-17F, and it is being developed across dermatology and rheumatology indications such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. MoonLake’s work centers on advancing targeted immunology treatments for conditions with significant unmet medical needs, positioning the company within the broader biopharmaceutical sector. Its Class A Ordinary Shares provide public-market exposure to a company whose current business is concentrated on clinical development and related biotechnology operations.

Website

Location

Dorfstrasse 29

Zug, 6300

Switzerland

Social

What share of all stock conversation is about MLTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% +0	0% +0	0% -0.01	0.01% +0.01

Sep 29

The company's drug is expected to submit a BLA (Biologics License Application) and is worth an estimated $400 million, which may not be a significant commercial opportunity.
The company's BLA submission is expected by the end of September, and the stock's current valuation is approximately $545 million, with a pro forma cash balance of $565 million.
The company's short fee rate is increasing, suggesting that there is a struggle to find shares to continue the shorts, and the stock has dropped to $12.04, with some investors feeling beaten up.

Generated by AI

Sentiment

Of the messages about MLTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	84.38% +28.13	65.06% +5.51	68.39% -4.47	82.73% +21.88
Bearish	15.63% -28.13	34.94% -5.51	31.61% +4.47	17.27% -21.88

Bullish· Aug 13

MoonLake Immunotherapeutics is expected to receive approval for its blockbuster drug within 4-5 months, which could significantly impact the stock price.
H.C. Wainwright has upgraded MoonLake's price target to $50, citing the drug's potential and the company's progress.
The company's recent ACR50 result of 42% could be a catalyst for further growth, as at least one analyst is not interpreting it as thesis-breaking.

Bearish· Sep 11

The company's management has been criticized for its communication, with some investors expressing frustration over the lack of updates on important trial data and conference events.
The stock has experienced significant price drops, with some investors suggesting that the company's valuation is now pricing a major failure, and that the pricing is "insane".
The company's management has been accused of playing games and making mistakes, and the recent price action has been attributed to funds dumping and retail investors being "along for the ride".

Generated by AI

Topics

Of the messages about MLTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	78.57%	95.61%	25.49%
Technical Analysis	—	21.43%	3.9%	14.75%
Analysts	—	0%	0.49%	33.55%
Controversies	—	0%	0%	1.71%
Earnings	—	0%	0%	0.93%
Macro	—	0%	0%	23.57%

Analysts· Jan 15

Goldman Sachs analyst Richard Law downgraded MoonLake Immunotherapeutics ($MLTX) to Sell from Neutral, citing high approval risks despite progress in Phase 3 trials.
The downgrade was met with skepticism by some, who pointed out that the analyst's previous upgrade and price target had been overly optimistic, and that the company's Phase 3 trials had shown promising results.
Multiple analysts, including Clear Street, H.C. Wainwright, and BTIG, have set price targets for $MLTX ranging from $24 to $45, indicating a bullish outlook for the company.

Announcements· Jun 22

MoonLake Immunotherapeutics reported strong one-year Phase 3 results for its lead HS treatment, Sonelokimab, with a 10%+ advantage over a competing IL-17 inhibitor.
The company announced positive findings from its Phase 3 VELA-1 and VELA-2 studies of sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, with 67.2% of treated patients achieving a HiSCR75 response at 52 weeks.
MoonLake Immunotherapeutics announced a proposed public offering of up to $150 million to fund commercialization, leverage positive data, strengthen negotiating power, and de-risk regulatory timelines for its sonelokimab program.

Technical Analysis· Jan 8

$MLTX is breaking out of its lower high in the mid 16s, with a potential base forming over the previous high in line with VWAP/EMA support.
The stock's structure is still biased towards the $20 area, with a trendline breakout attempt failing but a second attempt looking stronger and potentially pushing toward VWAP.
A reclaim of the VWAP and a downtrend trendline break could flip the stock into a clear uptrend toward the $20S, but short and rebuy pressure may need to be reloaded before a strong price reaction.

Generated by AI

Community

Of the messages about MLTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	89.71%	91.82%	79.91%	47.68%
Newcomers	10.29%	8.18%	20.09%	52.32%

Regulars· Sep 29

The regulars are discussing the upcoming BLA (Biologics License Application) submission, with some expressing concern that it may be delayed beyond the end of September.
The potential commercial value of the drug is being debated, with some estimating that Merck could generate $2B+ with a good commercial effort, but questioning whether the current management team has the interest or ability to build a commercial business.
The regulars are also discussing the short fee rate for $MLTX, which is finally starting to move upward, and speculating that the shorts may be struggling to find shares to continue their positions.

Newcomers· Sep 11

The recent stock drop to $11.95 and subsequent recovery to $18.49 has raised concerns about the company's management, with some users criticizing the lack of communication and transparency from the company's leadership.
The uncertainty surrounding the company's prospects, particularly with regards to the IZAR/VELA studies and the potential for a buyout or going solo, has led to a decline in the stock's value and a reevaluation of the company's worth.
The company's management is under scrutiny, with some users questioning the CEO's decisions, such as the handling of the conference fireside chat, the recent stock drop, and the lack of a webcast for shareholders, which has led to a decline in the stock's value and a loss of confidence among investors.

Generated by AI

MoonLake Immunotherapeutics

Social

Sep 29

Bullish· Aug 13

Bearish· Sep 11

Analysts· Jan 15

Announcements· Jun 22

Technical Analysis· Jan 8

Regulars· Sep 29

Newcomers· Sep 11

Cantor Fitzgerald reiterates Moonlake stock rating at Overweight

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital

MoonLake Immunotherapeutics (MLTX) Gets a Buy from BTIG

Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

Also Discussed

MoonLake Immunotherapeutics Class A Ordinary Shares

Company Information

Location

Cantor Fitzgerald reiterates Moonlake stock rating at Overweight

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital

MoonLake Immunotherapeutics (MLTX) Gets a Buy from BTIG

Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

Also Discussed

Social

Sep 29

Bullish· Aug 13

Bearish· Sep 11

Analysts· Jan 15

Announcements· Jun 22

Technical Analysis· Jan 8

Regulars· Sep 29

Newcomers· Sep 11